Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
作者信息
Park Jihye, Cheon Jae Hee
机构信息
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
出版信息
Gut Liver. 2021 Sep 15;15(5):641-642. doi: 10.5009/gnl210345.
Abstract
摘要
相似文献
1
Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?炎症性肠病患者能否停用抗肿瘤坏死因子药物？
Gut Liver. 2021 Sep 15;15(5):641-642. doi: 10.5009/gnl210345.
2
Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis.抗肿瘤坏死因子 α 制剂治疗炎症性肠病患者的淋巴瘤风险：系统评价和荟萃分析。
J Crohns Colitis. 2018 Aug 29;12(9):1042-1052. doi: 10.1093/ecco-jcc/jjy065.
3
A Narrative Review on Anti-Tumor Necrosis Factor α Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact.关于妊娠期炎症性肠病中抗肿瘤坏死因子α疗法的叙述性综述：免疫球蛋白的胎盘转运及其影响
Acta Med Port. 2019 Apr 30;32(4):305-312. doi: 10.20344/amp.11482.
4
Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.接受抗肿瘤坏死因子α制剂治疗的炎症性肠病儿科患者中的银屑病和银屑病样皮疹
Pediatr Dermatol. 2017 May;34(3):253-260. doi: 10.1111/pde.13081. Epub 2017 Feb 17.
5
Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.炎症性肠病患者接受肿瘤坏死因子拮抗剂治疗后出现银屑病：一项新的系列研究及对文献中 120 例病例的回顾。
Aliment Pharmacol Ther. 2011 Dec;34(11-12):1318-27. doi: 10.1111/j.1365-2036.2011.04866.x. Epub 2011 Sep 29.
6
Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.未来的新型药物：炎症性肠病中抗TNF药物之外的治疗方法
J Dig Dis. 2014 Nov;15(11):585-90. doi: 10.1111/1751-2980.12193.
7
Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study.炎症性肠病患者在临床缓解后停用抗肿瘤坏死因子-α治疗的长期结局：韩国肠病研究协会多中心研究。
Gut Liver. 2021 Sep 15;15(5):752-762. doi: 10.5009/gnl20233.
8
Evaluation of de-escalation of anti-TNF-α therapy in inflammatory bowel disease.炎症性肠病中抗TNF-α治疗方案降级的评估
Gastroenterol Hepatol. 2019 Feb;42(2):133-140. doi: 10.1016/j.gastrohep.2018.10.010. Epub 2018 Dec 27.
9
Anti-Tumor Necrosis Factor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients.抗肿瘤坏死因子-α诱导的炎症性肠病患者大队列中的皮肤科并发症。
Dig Dis Sci. 2018 Mar;63(3):746-754. doi: 10.1007/s10620-018-4921-y. Epub 2018 Jan 18.
10
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor therapies. Foreword.英夫利昔单抗及其他抗肿瘤坏死因子疗法治疗炎症性肠病。前言。
BioDrugs. 2010 Dec 14;24 Suppl 1:1-2. doi: 10.2165/11586300-000000000-00000.
本文引用的文献
1
Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.在缓解期溃疡性结肠炎患者中停用英夫利昔单抗（HAYABUSA）：一项多中心、开放标签、随机对照试验。
Lancet Gastroenterol Hepatol. 2021 Jun;6(6):429-437. doi: 10.1016/S2468-1253(21)00062-5. Epub 2021 Apr 20.
2
Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study.炎症性肠病患者在临床缓解后停用抗肿瘤坏死因子-α治疗的长期结局：韩国肠病研究协会多中心研究。
Gut Liver. 2021 Sep 15;15(5):752-762. doi: 10.5009/gnl20233.
3
Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn's disease: 3-year results from a real-world study.阿达木单抗在日本克罗恩病患者中的长期安全性和有效性：一项真实世界研究的3年结果
Intest Res. 2021 Oct;19(4):408-418. doi: 10.5217/ir.2020.00025. Epub 2020 Nov 20.
4
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study.阿达木单抗治疗溃疡性结肠炎的安全性和有效性：一项大规模、前瞻性、多中心观察性研究的结果
Intest Res. 2021 Oct;19(4):419-429. doi: 10.5217/ir.2020.00033. Epub 2020 Nov 10.
5
Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?英夫利昔单抗谷浓度与炎症性肠病患者不良事件的发生之间是否存在相关性？
Intest Res. 2021 Oct;19(4):461-467. doi: 10.5217/ir.2020.00042. Epub 2020 Aug 18.
6
Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy.肿瘤坏死因子抑制剂在合并恶性肿瘤患者中的使用安全性。
Intest Res. 2020 Jul;18(3):282-288. doi: 10.5217/ir.2019.09140. Epub 2020 Apr 7.
7
Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.停止英夫利昔单抗治疗后，接受抗代谢药物治疗的克罗恩病患者的缓解维持。
Gastroenterology. 2012 Jan;142(1):63-70.e5; quiz e31. doi: 10.1053/j.gastro.2011.09.034. Epub 2011 Sep 22.
Zotero 插件